Int J Biol Macromol. 2025 Sep 17;329(Pt 1):147767.
Abstract
Bone morphogenetic protein-2 (BMP2) has been approved by the United States Food and Drug Administration (FDA) to be used in human lumbar fusion to promote bone regeneration. However, BMP2 has a short half-life, rapid degradation, and burst release at high concentrations, which aggravates its adverse effects. A sodium alginate chitosan PEI-PBA-BMP2-ADSCs (SCPPBA) hydrogel was constructed. Hydrogel structure, biocompatibility, osteoinductivity, immunoregulation, and angiogenesis were evaluated. The SCPPBA hydrogel exhibited a porous structure, chemical crosslinking, moderate elastic modulus and viscosity, biocompatibility, biodegradation, and controlled and long-period BMP2 protein release. In an in vitro study, SCPPBA hydrogel exhibited osteoinductivity and immune modulation. We further implanted the SCPPBA hydrogel into a calvarial bone defect model in mice. The SCPPBA hydrogel exhibited excellent bone regeneration capacity and modulated macrophage polarization and angiogenesis in vivo. The SCPPBA hydrogel realizes the long-term controlled delivery of BMP2 and is suitable for BMP2 loaded implantation to promote bone regeneration
Products: YHC94201, Recombinant Human BMP2 Protein, N-His
